Allopurinol Adjuvant Therapy in Patients With Major Depressive Disorder
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:
• Patients aged greater than 18 years old. Patients with a HAM-D score of at least 10 with item 1, depressed mood, scoring 2 or greater, are eligible.
Locations
Other Locations
Egypt
Tanta Unuversity
RECRUITING
Tanta
Time Frame
Start Date: 2026-05-20
Estimated Completion Date: 2027-05-20
Participants
Target number of participants: 70
Treatments
Active_comparator: Control group
35 patients will receive Sertraline 50 mg/day plus a placebo.
Active_comparator: Allopurinol group
35 patients will receive 50 mg/day of sertraline plus allopurinol (300 mg/day).
Related Therapeutic Areas
Sponsors
Leads: Tanta University